Featured Research

from universities, journals, and other organizations

Rochester Study Rolls Out RU-486 To Treat Uterine Fibroids

Date:
December 7, 2006
Source:
University of Rochester Medical Center
Summary:
Low doses of the drug mifepristone shrink uterine fibroid tumors and greatly improve the quality of life in women who suffer from pain and heavy bleeding, according to a University of Rochester study published in the December Obstetrics and Gynecology journal.

Low doses of the drug mifepristone shrink uterine fibroid tumors and greatly improve the quality of life in women who suffer from pain and heavy bleeding, according to a University of Rochester study published in the December Obstetrics and Gynecology journal.

Related Articles


Leiomyoma, the medical term for uterine fibroids, affects roughly half of all women aged 35 to 49. The non-cancerous tumors cause iron-deficiency anemia due to excessive menstrual bleeding, and deeply impact the quality of life for women who have this condition. Thousands of women annually opt for hysterectomies or have the tumors removed surgically because no other medical treatment has been proven effective, the study said.

"With no approved treatment for symptomatic fibroids, this study and its findings are very significant," said corresponding author Kevin Fiscella, M.D., M.P.H., of the Department of Family Medicine Research Program at the University of Rochester Medical Center. "Interestingly, this is the same drug that was recently shown to prevent breast cancer in a rat model. Federal funding for research related to mifepristone should be given a high priority."

Doctors have known from prior data that mifepristone, an antiprogestin, might help uterine fibroids. But the benefits had not been confirmed until now. The University of Rochester study is the first randomized, double blind, placebo-controlled trial of mifepristone, also known as RU-486, to establish that it can be safely used at low doses to treat uterine fibroids. Forty-two premenopausal women from western New York volunteered to participate in the clinical trial from March 2004 to March 2005.

Of the total, 22 women received mifepristone at 5 mg daily, and 20 women received an identical looking placebo pill daily, for six months. Doctors sought to evaluate physical changes as well as quality of life improvements. To assess the latter, they used a survey with a 100-point scale that asked questions such as: "During the past month, how distressed were you by: heavy bleeding during your menstrual period, feeling tightness or pressure in your pelvic area, or feeling fatigued""

Researchers assessed bleeding with a daily log and hemoglobin tests, and administered ultrasound and other tests to assess uterine volume and tumor size. Safety monitoring was conducted throughout the trial. The National Institute of Child Health and Human Development funded the study.

Results were dramatic. By the end of the study, for example, virtually every woman in the mifepristone group was certain she had been receiving the drug because of so many improvements -- despite the study's intentional design to keep everyone "blind" to the data and outcomes.

Here are some statistics cited by the study authors: n Although quality of life measurements were the same for both groups at the start of the study, the women on mifepristone reported a 135-percent improvement in quality of life after six months, compared to a 41-percent improvement in the placebo group. Symptoms decreased in both groups, but severity was significantly less in the mifepristone group.

n Blood loss also improved among women taking mifepristone. For example, hemoglobin levels went up in the treatment group from 12.0 to 13.5 g/DL, compared to a decrease in hemoglobin levels in the placebo group. At the start of the study, 11 of 22 women (50 percent) in the mifepristone group were anemic, but after six months of treatment only 2 or 22 women (9 percent) were anemic. In the placebo group anemia rose, with 9 of 22 women (45 percent) anemic at the start of the study, and 12 of 22 women (60 percent) anemic after six months.

"These very promising findings warrant replication through a large multicenter study," the authors wrote. Further studies should evaluate whether the drug can be safely taken for longer periods, and how long after stopping the drug would regrowth of fibroids occur. Side effects to the drug were uncommon during the University of Rochester study, but the authors noted that adverse events should be carefully monitored during follow-up studies.

A few deaths have been reported among women taking mifepristone at much higher doses (200-600 mg.) for pregnancy termination. However, medical authorities have not established a causal relationship between mifepristone and the deaths.


Story Source:

The above story is based on materials provided by University of Rochester Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Rochester Medical Center. "Rochester Study Rolls Out RU-486 To Treat Uterine Fibroids." ScienceDaily. ScienceDaily, 7 December 2006. <www.sciencedaily.com/releases/2006/12/061207084009.htm>.
University of Rochester Medical Center. (2006, December 7). Rochester Study Rolls Out RU-486 To Treat Uterine Fibroids. ScienceDaily. Retrieved December 26, 2014 from www.sciencedaily.com/releases/2006/12/061207084009.htm
University of Rochester Medical Center. "Rochester Study Rolls Out RU-486 To Treat Uterine Fibroids." ScienceDaily. www.sciencedaily.com/releases/2006/12/061207084009.htm (accessed December 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, December 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

FDA Issues New Warning About Pure Caffeine Powder Usage

FDA Issues New Warning About Pure Caffeine Powder Usage

Newsy (Dec. 24, 2014) The FDA cites two deaths this year linked to pure caffeine powder as warnings of the potentially fatal substance. Video provided by Newsy
Powered by NewsLook.com
Alarming CDC Lab Report Reveals Ebola Sample Mix-Up

Alarming CDC Lab Report Reveals Ebola Sample Mix-Up

Newsy (Dec. 24, 2014) The Centers for Disease Control and Prevention released a report claiming a lab tech in Atlanta might have been exposed to the Ebola virus. Video provided by Newsy
Powered by NewsLook.com
French General Physicians Begin Strike, ER Doctors Back to Work

French General Physicians Begin Strike, ER Doctors Back to Work

AFP (Dec. 23, 2014) French doctors went on strike Tuesday in protest at an upcoming health bill. Emergency room doctors on the other end are returning to work after reaching an historic agreement. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
Malpractice Suit Changes Rule for Cruise Ships

Malpractice Suit Changes Rule for Cruise Ships

AP (Dec. 23, 2014) A recent court ruling may have opened the courthouse door for cruise ship passengers who claim poor treatment by ship medical personnel. (Dec. 23) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins